Zymeworks Collects a $250 Million Milestone for a Drug It Does Not Sell

by Carter Whitfield · August 25, 2026

Equities Reporter, The SmallCap Signal

Zymeworks said Tuesday that the U.S. Food and Drug Administration has approved two first-line regimens built around Ziihera, its bispecific HER2 antibody, in advanced gastroesophageal adenocarcinoma, and that the clearance triggers a $250 million milestone payment from its licensing partner Jazz Pharmaceuticals. It is the second FDA approval for the molecule, and it lands at a company that recorded $4.6 million of revenue in the three months to June 30.

According to the company's Aug. 25 announcement, the agency cleared Ziihera in combination with Tevimbra and fluoropyrimidine- and platinum-containing chemotherapy for adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma whose tumors are IHC 3+ or IHC 2+/ISH+, and separately cleared Ziihera plus the same chemotherapy backbone, without the immunotherapy, in the narrower IHC 3+ group. The two labels are not interchangeable, and the biomarker cut determines which one a patient falls under.

The clinical case rests on HERIZON-GEA-01, a Phase 3 study measured against trastuzumab plus chemotherapy. Jazz's own Aug. 25 release put median overall survival at 26.4 months for the Ziihera-plus-Tevimbra-plus-chemotherapy arm against 19.2 months for the comparator, which the release describes as a 28 percent reduction in the risk of death, with median progression-free survival of 12.4 months versus 8.1 months, described as a 35 percent reduction in the risk of disease progression or death. Results were published in the New England Journal of Medicine. Geoffrey Ku of Memorial Sloan Kettering, a co-author on the study, said in the release that "similar outcomes were seen in patients whose tumors were PD-L1 positive or PD-L1 negative," a point that matters because PD-L1 status often gates access to checkpoint inhibitors in this setting.

The commercial architecture is what makes Zymeworks unusual among small-cap biotechs. It does not sell Ziihera. Jazz holds exclusive development and commercialization rights in certain territories; BeOne Medicines, formerly BeiGene, holds rights across its licensed Asia-Pacific territories and owns Tevimbra. Zymeworks is paid in milestones and royalties on someone else's revenue line.

On the Jazz side, the company said Tuesday's approval brings cumulative upfront and milestone payments received from Jazz to $650 million, and that it remains eligible for up to $1.3 billion in further regulatory and commercial milestones plus tiered royalties of 10 percent to 20 percent on Jazz's net sales of zanidatamab. On the BeOne side, Zymeworks said it has received $81 million to date, is eligible for up to $144 million more, and earns tiered royalties of up to 19.5 percent on net sales in BeOne's territories.

"This second FDA approval for zanidatamab represents a significant milestone for Zymeworks and reinforces the strength of our scientific innovation engine," Kenneth Galbraith, the company's chair and chief executive, said in the announcement.

The payment is real cash and it is also, by construction, non-recurring. Milestones arrive once per event. What compounds is the royalty stream, and that depends entirely on how quickly Jazz and BeOne convert a label into prescriptions in a tumor type where the standard of care has been trastuzumab-based for years. Zymeworks does not report Jazz's sales; investors will read the trajectory out of Jazz's quarterly filings, not Zymeworks'.

The baseline underneath is a research-stage cost structure. In results released Aug. 6, Zymeworks reported second-quarter revenue of $4.6 million and a GAAP net loss of $45.0 million, with research and development expense of $27.4 million and general and administrative expense of $19.3 million. Cash, cash equivalents and marketable securities stood at $322.5 million as of June 30. In the same release the company said it no longer intends to provide cash runway guidance, on the view that it is transitioning to a revenue-generating business with multiple anticipated recurring cash flow streams.

That is a defensible position once a $250 million milestone is in hand, but it also removes a number investors had been using. With the milestone, the balance sheet is materially larger than the June 30 figure; without runway guidance, the burn math is left to the reader, and the operating loss run rate has not changed.

The label carries real constraints. The prescribing information includes a Boxed Warning for diarrhea and for embryo-fetal toxicity. In the 330-patient Ziihera-plus-Tevimbra-plus-chemotherapy safety population described in Tuesday's approval release, diarrhea occurred in 85 percent of patients, with Grade 3 events in 24 percent and Grade 4 in 2.1 percent, and fatal outcomes in 1.5 percent. Loperamide prophylaxis is required during the first cycle, and the warning flags a higher risk of severe and life-threatening diarrhea in patients aged 65 and over. A decline in left ventricular ejection fraction of more than 10 percentage points to below 50 percent was seen in 9 percent of patients, and fatal left ventricular dysfunction occurred in 0.3 percent.

Tolerability of that kind does not prevent an approval, but it does shape uptake, particularly in a first-line setting where oncologists have an established alternative. The regimen's survival advantage is the argument; the diarrhea management burden is the friction.

Zymeworks now has a marketed molecule with three Breakthrough Therapy designations and two Fast Track designations behind it, a second approved indication, and no direct control over the commercial effort that determines its royalty income. That is the trade the company made when it licensed the asset out, and Tuesday's payment is the clearest illustration of it so far.